Effectiveness of Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children: a Randomized, Double-blind Placebo Controlled Trial
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2015
Price : $35 *
At a glance
- Drugs Lactobacillus reuteri (Primary)
- Indications Diarrhoea
- Focus Therapeutic Use
- 06 Nov 2015 Primary endpoint (incidence of nosocomial diarrhoea) has not been met, according to results published in the Pediatric Infectious Disease Journal.
- 06 Nov 2015 Results published in the Pediatric Infectious Disease Journal
- 17 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.